JP2006502236A5 - - Google Patents

Download PDF

Info

Publication number
JP2006502236A5
JP2006502236A5 JP2004568900A JP2004568900A JP2006502236A5 JP 2006502236 A5 JP2006502236 A5 JP 2006502236A5 JP 2004568900 A JP2004568900 A JP 2004568900A JP 2004568900 A JP2004568900 A JP 2004568900A JP 2006502236 A5 JP2006502236 A5 JP 2006502236A5
Authority
JP
Japan
Prior art keywords
tgf
pharmaceutical composition
disease state
related disease
scleroderma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2004568900A
Other languages
English (en)
Other versions
JP2006502236A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/003825 external-priority patent/WO2004026307A1/en
Publication of JP2006502236A publication Critical patent/JP2006502236A/ja
Publication of JP2006502236A5 publication Critical patent/JP2006502236A5/ja
Abandoned legal-status Critical Current

Links

Claims (2)

  1. 治療上有効量の請求項1に記載の化合物を含む、動物またはヒトにおけるTGF関連の疾患状態の予防または治療のための医薬組成物。
  2. TGF関連の疾患状態が、癌、糸球体腎炎、糖尿病性腎障害、肝線維症、肺線維症、内膜過形成および再狭窄、強皮症、および皮膚の瘢痕化からなる群より選ばれる、請求項11に記載の医薬組成物。
JP2004568900A 2002-09-18 2003-09-08 形質転換成長因子(tgf)阻害剤としてのトリアゾール誘導体 Abandoned JP2006502236A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41207902P 2002-09-18 2002-09-18
US48453503P 2003-07-02 2003-07-02
PCT/IB2003/003825 WO2004026307A1 (en) 2002-09-18 2003-09-08 Triazole derivatives as transforming growth factor (tgf) inhibitors

Publications (2)

Publication Number Publication Date
JP2006502236A JP2006502236A (ja) 2006-01-19
JP2006502236A5 true JP2006502236A5 (ja) 2006-10-05

Family

ID=32033582

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004568900A Abandoned JP2006502236A (ja) 2002-09-18 2003-09-08 形質転換成長因子(tgf)阻害剤としてのトリアゾール誘導体

Country Status (25)

Country Link
US (2) US7053095B2 (ja)
EP (1) EP1542685A1 (ja)
JP (1) JP2006502236A (ja)
KR (1) KR20050057393A (ja)
CN (1) CN1681502A (ja)
AP (1) AP2005003260A0 (ja)
AR (1) AR041276A1 (ja)
AU (1) AU2003260810A1 (ja)
BR (1) BR0314577A (ja)
CA (1) CA2497971A1 (ja)
CO (1) CO5540390A2 (ja)
EA (1) EA200500376A1 (ja)
EC (1) ECSP055681A (ja)
HR (1) HRP20050251A2 (ja)
IS (1) IS7713A (ja)
MA (1) MA27442A1 (ja)
MX (1) MXPA05002982A (ja)
NO (1) NO20051010L (ja)
OA (1) OA12927A (ja)
PA (1) PA8583401A1 (ja)
PE (1) PE20050074A1 (ja)
PL (1) PL375974A1 (ja)
TW (1) TW200412346A (ja)
UY (1) UY27981A1 (ja)
WO (1) WO2004026307A1 (ja)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
CN1681810A (zh) 2002-09-18 2005-10-12 辉瑞产品公司 作为转化生长因子(tgf)抑制剂的新的噁唑和噻唑化合物
AP2005003264A0 (en) * 2002-09-18 2005-03-31 Pfizer Prod Inc Novel imidazole compounds as transforming growth factor (TGD) inhibitors.
AU2003259475A1 (en) * 2002-09-18 2004-04-08 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (TGF) inhibitors
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
EP1854789B1 (en) 2005-02-23 2013-10-09 Shionogi & Co., Ltd. Quinazoline derivative having tyrosine kinase inhibitory activity
ES2408597T3 (es) * 2005-07-25 2013-06-21 Synta Pharmaceuticals Corporation 1,2,3-triazoles inhibidores de la polimerización de la tubulina para el tratamiento de trastornos proliferativos
US20070142376A1 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
DE102005061840A1 (de) 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8673929B2 (en) 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
WO2013078286A1 (en) 2011-11-22 2013-05-30 Cornell University Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling
PL3685855T3 (pl) 2012-10-05 2024-04-08 Kadmon Corporation, Llc Ludzkie przeciwciała anty-vegfr-2/kdr
KR102168088B1 (ko) 2013-03-14 2020-10-20 더 브리검 앤드 우먼즈 하스피털, 인크. 상피 줄기 세포 확장 및 배양을 위한 조성물 및 방법
CA2935392C (en) 2014-01-01 2022-07-26 Medivation Technologies, Inc. Amino pyridine derivatives for the treatment of conditions associated with excessive tgf.beta activity
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
UA123090C2 (uk) 2015-03-04 2021-02-17 Гіліад Сайєнсіз, Інк. 4,6-ДІАМІНОПІРИДО[3,2-d]ПІРИМІДИНОВІ СПОЛУКИ, ЯКІ МОДУЛЮЮТЬ TOLL-ПОДІБНІ РЕЦЕПТОРИ
EP3400286A1 (en) 2016-01-08 2018-11-14 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
EP3507276B1 (en) 2016-09-02 2021-11-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
MX2019007890A (es) 2016-12-30 2020-01-20 Frequency Therapeutics Inc Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
EP3827010A4 (en) 2018-07-23 2022-03-16 Brise Pharmaceuticals Co., Ltd. BISPHOSPHONATE-DRUG CONJUGATES
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
AU2019419414A1 (en) 2018-12-31 2023-04-06 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN112694477B (zh) * 2019-10-22 2024-02-06 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物,包含其的药物组合物,其制备方法及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6058981A (ja) * 1983-09-09 1985-04-05 Takeda Chem Ind Ltd 5−ピリジル−1,3−チアゾ−ル誘導体,その製造法およびそれを含んでなる医薬組成物
JPS6025142A (ja) 1983-07-21 1985-02-07 Matsushita Electric Ind Co Ltd 表示装置の電極製造方法
EP0149884B1 (en) * 1983-09-09 1992-12-16 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-thiazole derivatives, their production and use
GB9201692D0 (en) * 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
JP2002502380A (ja) 1997-05-22 2002-01-22 ジー.ディー.サール アンド カンパニー p38キナーゼ阻害剤としてのピラゾール誘導体
KR20010012808A (ko) 1997-05-22 2001-02-26 윌리암스 로저 에이 p38 키나아제로서 4-아릴-3(5)-헤테로아릴 치환 피라졸
CA2302417A1 (en) * 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
ES2187473T3 (es) 1999-04-09 2003-06-16 Smithkline Beecham Corp Triarylimidazoles.
JP2000302680A (ja) * 1999-04-23 2000-10-31 Takeda Chem Ind Ltd 脳保護剤
AU6471300A (en) * 1999-08-06 2001-03-05 Takeda Chemical Industries Ltd. P38map kinase inhibitors
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
WO2002040468A1 (en) 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
GB0027987D0 (en) 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
EP1354603A1 (en) * 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
ES2237671T3 (es) 2001-02-02 2005-08-01 Smithkline Beecham Corporation Derivados de pirazol contra la sobreexpresion de tgf.
GB0102668D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US20040077697A1 (en) * 2001-02-02 2004-04-22 Hiroyuki Koshio 2-Acylaminothiazole derivative or its salt
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US20040097502A1 (en) 2001-02-02 2004-05-20 Gellibert Francoise Jeanne Pyrazoles as tgf inhibitors
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
EP1402900A1 (en) * 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Medicinal compositions
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
GB0217780D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
JP2005539000A (ja) 2002-07-31 2005-12-22 スミスクライン・ビーチャム・コーポレイション Alk5阻害剤としての2−フェニルピリジン−4−イル誘導体

Similar Documents

Publication Publication Date Title
JP2006502236A5 (ja)
HK1214253A1 (zh) -噁二唑苯甲酸化合物及其在無義抑制和疾病治療中的用途
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
JP2007523049A5 (ja)
HK1126119A1 (en) Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3- propanaediol derivative as active ingredient, and its use in manufacture of medicines for preventing or treating inflammatory bowel disease 2--13-
CL2007001131A1 (es) Compuestos derivados de purina sustituida; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
HK1085720A1 (en) Substituted phenylalkanoic acid derivatives and their use for respiratory disease treatment
JP2005537234A5 (ja)
JP2005500357A5 (ja)
JP2006504723A5 (ja)
JP2008513426A5 (ja)
NO20043370L (no) N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
JP2009518415A5 (ja)
ATE448232T1 (de) Substituierte heterozyklen
JP2005507892A5 (ja)
JP2008513427A5 (ja)
JP2006514116A5 (ja)
JP2005511619A5 (ja)
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
JP2005507888A5 (ja)
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
DE112004001618D2 (de) Pharmazeutischer Wirkstoff gegen Tumorerkrankungen
MX2009006670A (es) Composicion farmaceutica que usa el aliskiren y el avosentan.